An observational study in Analgesic Quality and Mobility, sponsored by University Hospital Tuebingen. Status unknown at 1 site in Germany. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-28.
Sponsored by University Hospital Tuebingen · Observational
The observational study will check if there is a difference in the postoperative care of patients with urogenital intervention while using the standard PCA-syringe pump or using the Zalviso sufentanyl sublingual analgetic system.
The study will exactly examine, using questionaire for the patient, the medical stuff (nurses and anesthesiologist) the difference in the analgetic quality, the difference of the patients' mobility while being treated with one of the analgetic system and if there is a difference in the cost-efficiency.
We want to examine 50 Patients in each group. The studies should be finished in about one year.
All patients at the teaching hospital of university tuebingen which get an surgical urological intervention and which correspond with the inclusion criteria.
Exclusion Criteria:
Drug: Sufentanil
Sufentail sublingual 15ug nanopills
analgesic quality
Recording of the analgesic quality measured by the request of more analgesic postoperative while being treated with the conventional PCA or the Zalviso system.
Time frame: 1 year
mobility
Recording of the patients mobility postoperative while being treated with the conventional PCA or the Zalviso system.
Time frame: 1 year
medical cost efficiency
Comparison of the cost efficiency of both systems
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Tuebingen